Efficacy and Safety of Fixed-dose Combination of Etoricoxib/Tramadol vs Acetaminophen/Tramadol for Acute Low Back Pain

Exclusion Criteria

• •Patients in whom the study drug is contraindicated for medical reasons.
• •Patients with an allergy or hypersensitivity to the active principle, study drugs, related products or excipients.
• •Positive pregnancy test, women who are pregnant, breastfeeding or planning a pregnancy while conducting the study.
• •A significant history of gastrointestinal disorders (for example: Gastric ulcer, Crohn's disease, Ulcerative Colitis, etc.).
• •Previous treatment with opioids and / or NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) reported in the medical history in the last 72 hours at study entry.
• •Patients with a history of alcohol or drug abuse in the last year according to DSM-V (Diagnostic and Statistical Manual of Mental Disorders).
• •Patients who are receiving monoamine oxidase inhibitors (MAOIs) or who have received them within the past 2 weeks.
• •Patients with a history of established ischemic heart disease, peripheral arterial disease and / or cerebrovascular disease (including patients who have recently undergone coronary artery bypass grafting or angioplasty).
• •Patients with status epileptic seizure disorders and grand mal seizures.
• •Patients with a history of severe acute or chronic liver failure.
• •Patients with a history of moderate to severe renal failure.
• •Patient with a history of chronic pain (eg, fibromyalgia, Paget's disease, bone pain induced by metastatic cancer).
• •Low back pain due to major trauma (eg vertebral fracture, post-traumatic spondylolisthesis), or due to a visceral disorder (eg dysmenorrhea, endometriosis).
• •At medical criteria, a disease that affects the prognosis and prevents outpatient management, for example, but not restricted to: intestinal obstruction, paralytic ileus, end-stage cancer, kidney, heart, respiratory or liver failure or mental illness or with surgical procedures or scheduled hospitals.
• •History / presence of any disease or condition that, in the Investigator's opinion, could pose a risk to the patient or confuse the efficacy and safety of the study results. ----Patients with symptoms suggesting an active COVID-19 infection (i.e., fever, cough, dyspnea) and / or contact in the past 14 days with a suspected or positive COVID-19 patient.
• •Oncological patients (except basal cell skin cancer) or with serious diseases that, in the opinion of the investigator, have a serious prognosis or a life expectancy of less than 1 year, as well as mental illnesses.
• •The patient is participating in another clinical study involving an investigational treatment or participated in one in the previous 4 weeks.
• •Patients whose participation in the study may be influenced (employment relationship with the research center or sponsor, inmates, etc.).